메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

PT Fapon and PT Bio Farma Forge Strategic Partnership to Adv…

DONGGUAN, China, Dec. 8, 2025 -- PT Fapon Bioindustries Indonesia (referred to as "PT Fapon") and the Indonesian state-owned pharmaceutical holding company PT Bio Farma (Persero) (referred to as "Bio Farma") officially signed a cooperation agreement at Fapon's headquarters in Dongguan. The partnership is centered on the local manufacturing, and commercialization of IVD products in Indonesia. Mrs. Dyah, Chief Executive Officer of Fapon Indonesia Market, and Mr. Dicky, Head of the Business Development Division at Bio Farma, formally executed the agreement on behalf of their respe
- 김갑성 기자
- 2025-12-08 20:47
Servier's Voranigo® (vorasidenib) Receives Prix Galien Award…

Voranigo® has been awarded the Prix Galien USA, the Prix Galien Poland and the Prix Galien Bridges Awards for Best Product for Orphan/Rare Diseases. These awards across several geographies recognize the progress represented by Voranigo® for patients living with glioma. SURESNES, France, Dec. 8, 2025 -- Servier, an independent international pharmaceutical group governed by a foundation, today announced that Voranigo® (vorasidenib) has been awarded the inaugural 2025 Prix Galien Bridges Award for Best Product for Orphan/Rare Diseases, during a ceremony held in
- 김갑성 기자
- 2025-12-08 20:24
Aurora Names Seasoned Global CPG Executive to Lead Austr…

NASDAQ | TSX: ACB EDMONTON, AB, Dec. 8, 2025 -- Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, announces Kerry Miller, a 35-year consumer packaged goods executive, as Managing Director for Australia and New Zealand, effective January 15, 2026. Kerry will be instrumental in driving growth in these key markets, drawing on decades of global experience in fast moving, regulated industries. "I'm excited to join Aurora at an inflection point in the company's global leadership and to work alongside a team dedicate
- 김갑성 기자
- 2025-12-08 20:00
Ascletis' Oral Small Molecule GLP-1, ASC30, Demonstrated Place…

- ASC30 once-daily tablets showed statistically significant and clinically meaningful dose-dependent placebo-adjusted mean body weight reductions with no observed plateau for weight loss. - ASC30 titrated weekly to target dose demonstrated approximately one-half the rate of vomiting observed with orforglipron titrated weekly. - No hepatic safety signal was observed, and no elevations of alanine transaminase (ALT), aspartate aminotransferase (AST) or total bilirubin (TBL) were observed. - Two conference calls/webcasts are scheduled to discuss the results, including a
- 김갑성 기자
- 2025-12-08 17:40
ELFBAR takes a bold step in restrained design with its award…

LONDON, Dec. 8, 2025 -- Leading global vape brand ELFBAR today announced it has earned three global design awards — the Pentawards, the Red Dot Award*, and the London Design Awards — for its boldly restrained design of the ELFA PRO Nicotine Reduction Kit, the first ever of its kind created to help adult smokers and vapers quit nicotine for good. Visualising the journey beyond nicotine The ELFA PRO Nicotine Reduction Kit, a classic ELFBAR pod system, is designed as a three-phase, 90-day pathway that gradually lowers nicotine intake from 2% to 1% and then to 0%. Th
- 김갑성 기자
- 2025-12-08 17:00
엘프바의 과감한 시도, 절제된 디자인이 돋보이는 니코틴 감축 키트의 잇따른 수상

런던 2025년 12월 8일 -- 세계적인 전자담배 브랜드 엘프바(ELFBAR)는 오늘 성인 흡연자와 전자담배 애용자의 금연을 돕는 업계 최초의 엘파 프로 니코틴 감축 키트(ELFA PRO Nicotine Reduction Kit)가 대담하면서도 절제된 디자인에 힘입어 세계적인 디자인 어워드인 펜타어워즈(Pentawards), 레드닷 어워드(Red Dot Award)*, 런던 디자인 어워즈(London Design Awards)를 잇따라 수상하는 쾌거를 이뤘다고 발표했다. 체계적인 금연 계획 엘프바의 전통적인 액상 팟 교체 방식의 엘파 프로 니코틴 감축 키트는 90일 동안 3단계로 나눠 니코틴 함유량을 2%에서 1%, 그리고 최종적으로 0%로 점차 줄이도록 설계되었다. 금연 과정은 1개월 단위의 3단계(1~30일 차, 31~60일 차, 61~90일 차)로 나뉘어 있으며, 단계마다 니코틴 함량이 대폭 줄어든다. 제품 사용자가 니코틴에서 완전히 해방될 수 있도록 돕는 각 단계는 행동 변화에 흔히 수반되는 감정적 흐름을 반영하여 '각성(Awaken)', '수용(Embrace)', '변화(Trans
- 김갑성 기자
- 2025-12-08 17:00
Qualcomm Highlights Edge AI Innovation at Qualcomm AI Progr…

[ 메디채널 김갑성 기자 ] Showcasing transformative edge AI innovations across robotics, healthcare and smart city solutions SEOUL, South Korea, Dec. 8, 2025 -- Qualcomm Technologies, Inc. hosted the Qualcomm AI Program for Innovators (QAIPI) 2025 – APAC Demo Day in Seoul, where 15 shortlisted startups from Japan, Singapore, and South Korea presented on-device AI solutions by leveraging Snapdragon® X Series processors, Snapdragon® 8 Series Mobile Platforms and Qualcomm Dragonwing™ products. These solutions demonstrate how real-time, power-efficient AI inference runs directly on Qualcom
- 김갑성 기자
- 2025-12-08 16:28
UCB presents positive results from GEMZ phase 3 study at AES…

[ 메디채널 김갑성 기자 ] Seizure reduction: phase 3 study achieved primary endpoint as fenfluramine demonstrated a statistically significant reduction in countable motor seizure frequency (CMSF) compared with placebo1 Holistic benefit: secondary endpoints showed significant and clinically meaningful improvements in Clinical Global Impression–Improvement (CGI-I) in patients treated with fenfluramine compared with placebo1 Fenfluramine was generally well tolerated, with no new safety signals identified1 UCB plans to submit for regulatory approval of fenfluramine for the treatment of seizures asso
- 김갑성 기자
- 2025-12-08 15:25
GC Biopharma Ships First Doses of World's First Recombinant A…

- First anthrax vaccine developed using recombinant DNA technology- Annual production capacity of up to 10 million doses at GC Biopharma's facility YONGIN, South Korea, Dec. 8, 2025 -- GC Biopharma (006280.KS), a leading global biopharmaceutical company, today announced the first shipment of BARYTHRAX inj., the world's first recombinant anthrax vaccine. The product, jointly developed by the Korea Disease Control and Prevention Agency (KDCA) and GC Biopharma, was granted regulatory approval in April as Korea's 39th locally developed new drug. The initial su
- 김갑성 기자
- 2025-12-08 14:36
CARsgen Announces Data of Allogeneic BCMA CAR-T Cell The…

SHANGHAI, Dec. 8, 2025 -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that clinical data from its allogeneic BCMA-targeted CAR T-cell product candidate, CT0596, for the treatment of relapsed/refractory multiple myeloma (R/R MM) was presented in a poster at the 67th American Society of Hematology (ASH) Annual Meeting. The poster was titled "A First-in-Human Study of CT0596, an Allogeneic CAR T-Cell Therapy Targeting BCMA, in Patients with Relapsed/Refractory Multiple Myeloma." The publ
- 김갑성 기자
- 2025-12-08 10:08

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2025-12-10_WED

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 12월 10일 18시 20분